Flopropione, a Cysteine Conjugate β-Lyase 1 Inhibitor, for Prevention of Cisplatin-Induced Nephrotoxicity: Protocol for a Randomized, Open-Label, Proof-of-Concept Phase 1 and 2a Trial | Synapse
March 3, 2026Open Access
Flopropione, a Cysteine Conjugate β-Lyase 1 Inhibitor, for Prevention of Cisplatin-Induced Nephrotoxicity: Protocol for a Randomized, Open-Label, Proof-of-Concept Phase 1 and 2a Trial
Puntos clave
Flopropione significantly aims to prevent cisplatin-induced nephrotoxicity in a trial setting, showing promise for safer cancer treatments.
The main outcome is the incidence of nephrotoxicity during treatment with cisplatin over the trial duration.
Randomized open-label trial protocols are designed to assess flopropione's effectiveness as a nephroprotective agent and safety in patients.
Findings may support new strategies to enhance the safety of chemotherapy regimens, though results remain pending.